Dementia with Lewy bodies: A study of post-synaptic dopaminergic receptors with iodine-123 iodobenzamide single-photon emission tomography

European Journal of Nuclear Medicine

Volumn 24, Issue 6, 1997, Pages 609-614

  Walker, Zuzana ^a,b,g   Costa, Durval C ^a,c   Janssen, Anthony G ^d   Walker, Rodney W H ^b,e   Livingstone, Gillian ^b,f   Katona, Cornelius L E ^a,b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b PRINCESS ALEXANDRA HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^d EINDHOVEN UNIVERSITY OF TECHNOLOGY   (Netherlands)

^e ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^f WHITTINGTON HOSPITAL   (United Kingdom)

^g St Margaret's Hospital   (United Kingdom)

Author keywords

Alzheimer's disease; D2 receptors; Dementia with Lewy bodies; Iodine 123 iodobenzamide; Single photon emission tomography

Indexed keywords

DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR; IODINE 123; IODOBENZAMIDE I 123; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN TOMOGRAPHY; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DEMENTIA; DIFFERENTIAL DIAGNOSIS; DOPAMINE BRAIN LEVEL; FEMALE; FRONTAL CORTEX; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEWY BODY; MALE; NIGRONEOSTRIATAL SYSTEM; PHOTON EMISSION TOMOGRAPHY; PUTAMEN;

EID: 0030789972     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00841397     Document Type: Article

References (34)

1. Byrne EJ, Lowe J, Lennox G, Godwin-Austen RB. Diffuse Lewy body disease; clinical features in 15 cases. J Neurol Neurosurg Psychiatry 1989; 52: 709-717.
2. Lennox G, Lowe J, Landon M, Byrne EJ, Mayer RJ, Godwin-Austen RB. Diffuse Lewy body disease: correlative neuropathology using anti-ubiquitin immunocytochemistry. J Neurol Neurosurg Psychiatry 1989; 52: 1236-1247.
3. Dickson DW, Crystal HA, Mattiace HA, et al. Diffuse Lewy body disease: light and electron microscopic immunocytochemistry of senile plaques. Acta Neuropathol (Berl) 1989; 78: 572-584.
4. McKeith IG. Senile dementia of Lewy body type - a review of clinical and pathological features: implications for treatment. Int J Geriatr Psychiatry 1995; 10: 919-926.
5. Hely MA, Reid WGJ, Halliday GM, et al. Diffuse Lewy body disease: clinical features in nine cases without coexistent Alzheimer's disease. J Neurol Neurosurg Psychiatry 1996; 60: 531-538.
6. Shergill S, Mullan L, D'Ath PJ, Katona CLE. What is the clinical prevalence of Lewy body dementia. Int J Geriatr Psychiatr 1994; 9: 907-912.
7. Byrne EJ, Lennox G, Godwin-Austen RB, et al. Diagnosticcriteria for dementia associated with cortical Lewy bodies. Dementia 1991; 2: 283-284.
8. McKeith IG, Perry RH, Fairbairn AF, Jabeen S, Perry EK, Operational criteria for senile dementia of Lewy body type (SDLT). Pathol Med 1992; 22: 911-922.
9. Byrne EJ, Cortical Lewy body disease: an alternative view. In: Levy R, et al. Developments in dementia and functional disorders in the elderly. Petersfield, UK: Wrightson Biomedical, 1995: 21-30.
10. McKeith IG, Fairbairn AF, Bothwell RA, et al. An evaluation of the predictive validity and inter-rater reliability of clinical diagnostic criteria for senile dementia of Lewy body type. Neurology 1994; 44: 872-877.
11. Förstl H, Sattel H, Bahro M. Alzheimer's disease: clinical features, Int Rev Psychiatry 1993; 5: 327-349.
12. McKeith IG, Galasko D, Wilcock GK, Byrne EJ, Lewy body dementia - diagnosis and treatment. Br J Psychiatry 1995; 167: 709-717.
13. McKeith IG, Cortical Lewy body disease: the view from Newcastle. In: Levy R, et al. Developments in dementia and functional disorders in the elderly. Petersfield. UK: Wrightson Biomedical; 1995: 9-20.
14. Fearnley JM, Lees AJ, Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991; 114: 2283-2301.
15. Koller WC. When does Parkinson's disease begin? Neurology 1992; 42: 27-31.
16. Perry EK, Marshall E, Perry RH, et al. Cholinergic and dopaminergic activities in senile dementia of Lewy body type. Alzheimer Dis Assoc Disord 1990; 4: 87-95.
17. 18F-dopa and positron emission tomography. Neurology 1992; 42: 1894-1900.
18. 18F]-dopa positron emission tomography studies in an Irish kindred. Ann Neurol 1992; 32: 609-617.
19. Tyrell PJ, Sawle GV, Ibanez V. et al. Clinical and positron emission tomographic studies in the "extrapyramidal syndrome" of dementia of Alzheimer's type. Arch Neurol 1990; 47: 1318-1328.
20. Brooks DJ. Functional imaging in relation to purkinsonian syndromes. J Neurol Neurosurg Psychiatry 1993; 115: 1-17.
21. 123I in humans. Eur J Nucl Med 1990; 16: 813-816.
22. McKhana G, Drachman D, Folstein MF, Katzman R, Price D, Standlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984; 34: 939-944.
23. Hughes AJ, Daniel SK, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-184.
24. Folstein MF, Folstein SE, HcHugh PR. "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
25. Pattie AH, A survey version of the clifton assessment procedures for the elderly (CAPE). Br Clin Psychol 1981; 20: 173-178.
26. Yesavage JA. Geriatric Depression Scale. Psychopharmacol Bull 1988; 24: 709-711.
27. Berl L. Clinical Dementia Rating (CDR). Psychopharmacol Bull 1988; 24: 637-639.
28. Roth M, Tym E, Mountjoy CQ, et al. CAMDEX: a standardised instrument for the diagnosis of mental disorders in the elderly with special reference to the early detection of dementia. Br J Psychiatry 1986; 149: 698-709.
29. Brücke T, Podreka I, Angelberger P, et al. Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatric disorders. J Cereb Blood Flow Metab 1991; 11: 220-228.
30. 11C-raclopride and positron emission tomography. Ann Neurol 1992; 31: 184-192.
31. 2 dopamine receptors of patients with Parkinson's disease using single photon emission tomography and iodobenzamide I 123. Arch Neurol 1993; 50: 509-512.
32. 99mTc]-HM-PAO study. Eur Neurol 1993; 33: 143-148.
33. 2 receptor supersensitivity in the striatum of patients with early Parkinson's disease. Mov Disord 1990; 5: 55-59.
34. 2 receptor changes during the progression of early Parkinson's disease. Mov Disord 1993; 8: 134-138.